We would love to hear your thoughts about our site and services, please take our survey here.
Novartis raising guidance, also speaking of three emerging platforms ,( gene&cell therapy,radioligand therapy and xRNA) prioritized for continued investment into new R&D capabilities and manufacturing scale.
https://www.novartis.com/sites/novartis_com/files/q1-2024-investor-presentation.pdf
I did indeed.
He used $billion deals in the sector as a comparative to where perhaps he could see Avacta's real future value, if one were to look at the potential licence deals , AVA6000/3996 upfront, non core assets offloaded and/or Avacta Therapeutics inc being fast tracked ( just like the FDA is treating AVA6000) onto Nasdaq.
News embargo soon to be lifted, results next week and plenty of M&A building up in the sector, it is very tempting to apply, as mentioned by someone during a presentation, a billion dollar average to each of the AVA's ?
With coming up next week, another 3 trading days and with CEO mentioning several times during the Webinar " at upcoming results", it would be sensible to be increasing holdings today at current prices, in front of results and most likely proper news, like DX disposal and first AVA6000 license deal and AVA3996 update, now that would easily push the price back above 60 and onwards!
The market have finally worked out, that he is foremost a sciencetist and very proud of what the AVA portfolio have and will achieve. He is not a day trader or looking for short term gains.We have results coming up soon and it will also highlight what AVA3996 has achieved and considering the interest the second of the AVA family is having, with suggestings of the 3996 surprising on the upside and matching AVA6000 in commercial value or even exceeding it.
He made it very clear with regards to AVA6000, that the company will wait and receive the right deal, most likely with a major firm and that deal alone ( milestone payments etc ) will exceed the current market value of the company. Triple A investment funds have joined and it will not stop here. If you have the patience, buy more, the company has clearly been showed, what sort of sums we are talking about, with a license deal with a major.
And then the FDA fast tracking !
The period up to next set of numbers will be very " interesting".
Remember we now have the Ceo speaking of " billion dollar deals".